About us

Our mission

Improvement of our research, production and talent capacities to ensure production of high-technology effective and safe drugs to further develop domestic healthcare service and improve the health of the population.

Our mission

1960

The history of Public Joint Stock Company “Biosintez” begins in 1955, when several buildings of the future plant began to grow on the Penza outskirts. And after 4 years, in October 1959, the Company released the first products - biomycin antibiotic and vitamin B12.
In subsequent years, the plant intensively developed the production of substances by microbiological synthesis and became one of the largest pharmaceutical companies of the Soviet Union. The oleandomycin, tetracycline, nystatin, heliomycin, fusidine, levorin, griseofulvin, riboxin substances and some of other drugs were of high quality and stability.

1961

The plant development project included production of both substances and finished medicines of various dosage forms. Production of the first of them (tablets) was mastered just two years after the foundation of the Company, in 1961.

1971

1971 is the year of the start of production of sterile dosage forms. This year, integrated units for manufacturing infusion solutions in glass bottles and powders for injection were opened.

1986

In 1986, the Company launched while gradually increasing capacity of an integrated unit for manufacturing substances of animal and vegetable origin: insulin, heparin, pancreatin, valerian extract, sodium nucleinate.

1996

1998

In 1998, ampouled injectable solutions were added to the list of sterile dosage forms.

2002

The quality of manufactured products has always been the main objective of the Company, and in 2002 a new laboratory complex of the Quality Control Department was built and certified by the Ministry of Health of Russia for technical competence.

2006

Since 2005, modernization of the main production facilities has been actively started. For example, in 2006, according to the technical re-equipment plan, a new blister filling site was put into operation.

2007

In 2007, the Company launched production of cephalosporin powders for injections certified for the compliance with the EU GMP requirements.

2012

In 2012, the Advanced Research and Educational Center was created on the basis of the Biosintez Central Laboratory. As part of the implementation of the Federal Target Staff Training Program for Biomedical and Pharmaceutical Industries, the Company created an internship site aimed at improving academic mobility of teachers and students, developing innovative entrepreneurship skills in biomedical and pharmaceutical fields. At dedicated workplaces, students are able to get an understanding of both manufacturing process and procedures for production management, quality control and research and development in real production conditions.

2013

From 2009 to 2013, the Ministry of Industry and Trade of the Russian Federation repeatedly awarded OJSC “Biosintez” as the Best Exporter of the pharmaceutical industry and in different years the Company was awarded as the most dynamically developing exporter of the pharmaceutical industry, the best exporter to the CIS countries.

2014

From 2012 to 2014, the Company, a complete reconstruction and modernization of all production facilities of the Company was performed as part of the large-scale investment project "Modernization of production of medicines at OJSC “Biosintez”.

2015

Biosintez, PJSC is one of the first Russian companies to receive GMP certificate issued by the Ministry of Industry and Trade of the Russian Federation at the beginning of 2015.

2016

In December 2016, Biosintez became a member of Sun Pharmaceutical Industries Ltd. That was the first acquisition of San Pharma in Russia.
Sun Pharma is the fourth largest specialty generic pharmaceutical company in the world with manufacturing facilities in more than 150 countries.
Sun Pharma is famous for its high-quality medicines and trusted by patients and healthcare professionals across the globe.

2019

In October 2018, PJSC “Biosintez” passed a licensing audit for the compliance with the requirements of the Russian GMP standard (Good Manufacturing Practice).
The GMP Certificate was obtained as a result of the audit in January 2019.

2019

In May 2019, PJSC “Biosintez” launched a new site for manufacturing solid formulations with a capacity of up to 2 billion tablets per year, as well as a state-of-art logistics complex.

2020

In October 2020, PJSC “Biosintez” having making major preparatory efforts in close cooperation with the Industrial Development Fund (IDF) introduced the state drug labeling system at the Company. Currently, the system is installed on all packaging lines and operates in data transfer mode.

2022

At the beginning of 2022, PJSC “Biosintez” put a new gas boiler house into operation for the steam and hot water generation. This project allows the company to reduce the cost of thermal carriers and improve their quality, ensure uninterrupted operation of production shops through autonomous and independent steam supply.

2022

Today, PJSC “Biosintez” is a member of San Pharma group of companies and a large high-tech enterprise that meets the national standards of the pharmaceutical industry. Currently, the range of products of the Company includes more than 160 types of medicines and is heavily marketed in the Russian Federation, CIS countries and far abroad.

Indicators

3billion rubles.

The volume of production of the enterprise

Pharmaceutical market share

180names

preparations of various forms of release:

34%

Pills

16%

Injections

Ointments

32%

Powders

Infusions

Suppositories

Our values/div>

Reliability

We maintain efficiency and order in processes and systems; we fulfill obligations to shareholders and partners.

Quality

We do our work efficiently from the first time; each of us is responsible for quality, as it is above all.

Innovations

We strive to introduce new ideas and technologies, to meet other possible needs.

Trust

Won with great difficulty, it needs to be strengthened and conduct business transparently.

Stability

We strive to bring new products to the market and constantly increase the value companies for shareholders.

Quality

The company builds a quality system based on the principles of national and international (GMP EAEU) rules of good manufacturing practice, ICH Q10 (Pharmaceutical quality system) and other applicable regulatory documents of the pharmaceutical industry, in accordance with the procedures of Sun Pharma. The company's commitment to implementing a reliable and sustainable quality system is achieved through the continuous promotion of a culture of production improvement and quality compliance, meeting the expectations of our customers, stakeholders and government regulatory authorities.

Diploma "The best exporter of the Pharmaceutical industry in 2013"

Diploma "The best exporter of the Pharmaceutical industry in 2012"

Diploma "The best exporter of the Pharmaceutical industry in 2011"

Diploma "The best exporter of the Pharmaceutical industry in 2010"

Diploma "The best Russian exporter-2009" in the category "The most dynamically developing Russian exporter of the pharmaceutical industry"

Conclusion of the Ministry of Industry and Trade of the Russian Federation on compliance with the requirements of the Rules for the organization of production and quality control of medicines (GMP)

License for the production of medicines